in

Dun & Bradstreet CEO Robert Carrigan Adds Board Chairman Role; Thomas Manning Named Lead Director

Dun & Bradstreet CEO Robert Carrigan Adds Board Chairman Role; Thomas Manning Named Lead Director - top government contractors - best government contracting event
https://executivebiz-media.s3.amazonaws.com/2022/08/19/30/9f/c3/a0/b7/6f/d4/64/Executive-Biz.png

dun-bradstreet-logoRobert Carrigan, CEO of Dun & Bradstreet, has been selected to succeed the retiring Christopher Coughlin as the company’s chairman of the board.

Thomas Manning, a director at Dun & Bradstreet and member of the company’s audit and innovation & technology committees, was also named lead director and chairman of the firm’s nominating and governance committee, Dun & Bradstreet said Wednesday.

Coughlin, who became board chairman at Dun & Bradstreet in 2013, will continue to serve as a member of the board through May.

Carrigan, who has been CEO of Dun & Bradstreet since October 2013, previously served as chief executive of IDG Communications and worked for four years at America Online as senior vice president of the interactive marketing group.

Manning is former CEO at Indachin and Cerberus Asia Operations & Advisory and held senior leadership roles at Ernst & Young, Capgemini, McKinsey & Co. and Bain & Co.

He also serves as a director at Clear Media and CommScope Holding and is a lecturer in law at the University of Chicago Law School.

ExecutiveBiz Logo

Sign Up Now! ExecutiveBiz provides you with Daily Updates and News Briefings about Technology

mm

Written by Neel Mehta

Wayne Lewandowski on Vormetric's Integration Into Thales, Bookings Growth & Data Encryption Trends at Agencies - top government contractors - best government contracting event
Wayne Lewandowski on Vormetric’s Integration Into Thales, Bookings Growth & Data Encryption Trends at Agencies
General Atomics, Nordion to Get Phase II Funds from DOE to Support Medical Isotope Production - top government contractors - best government contracting event
General Atomics, Nordion to Get Phase II Funds from DOE to Support Medical Isotope Production